Stereotaxis CEO David Fischel says the MAGiC catheter was designed "to overcome the natural limitations of manual pull-wire ...
Dr Michele Orini shares how machine learning can help identify critical VT ablation targets for a safer, data-driven ...
Stereotaxis plans to launch the MAGiC cardiac ablation catheter in early 2026, CEO and Chair David Fischel tells MassDevice.
Researchers at RIT are developing non-invasive technology that will better assess cardiac tissue response to thermal energy, a common therapy approach for both cancer and cardiac arrhythmia treatments ...
Catheter ablation was not the first-line treatment for supraventricular tachycardia (SVT) for most patients referred to a tertiary center, a study shows, with investigators suggesting the procedure is ...
Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia, posing significant public health challenges due to its association with stroke, heart failure and diminished quality of ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) ...
BOSTON -- For persistent atrial fibrillation (Afib), adding artificial intelligence guidance for ablation site selection improved success, the TAILORED trial showed. Freedom from Afib after one ...
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback